Core Viewpoint - Filana Therapeutics is focused on advancing its Tuberous Sclerosis Complex (TSC)-related epilepsy program while maintaining capital efficiency, reporting significant financial results and operational updates for 2025 [1][4]. Financial Performance - The net loss for 2025 was $91.0 million, or $1.88 per share, compared to a net loss of $24.3 million, or $0.53 per share in 2024, with the increase primarily due to a lack of a $108.1 million gain from the change in fair value of warrant liabilities that occurred in 2024 [2][7]. - Net cash used in operations was $32.3 million in 2025, consistent with previous guidance, and the company estimates cash use in operations for the first half of 2026 to be between $14 million and $17 million [3][7]. - Cash and cash equivalents were reported at $95.5 million as of December 31, 2025, down from $128.6 million at the end of 2024, with an estimated cash range of $47 to $50 million by June 30, 2026 [3][7]. Research and Development - Research and development (R&D) expenses decreased significantly to $26.6 million in 2025 from $69.6 million in 2024, a reduction of 62%, primarily due to the phase-out of the Alzheimer's disease development program [7][8]. - General and administrative (G&A) expenses decreased to $68.8 million in 2025 from $71.8 million in 2024, reflecting a 4% decrease attributed to prior year contingencies and changes in compensation expenses [8]. Corporate Updates - The company has undergone a name change to Filana Therapeutics, Inc., reflecting its strategic focus on developing therapies targeting the filamin A protein for CNS disorders, including TSC-related epilepsy [7]. - Filana Therapeutics is actively addressing the FDA's requests for additional information related to its clinical hold on the investigational new drug application for simufilam in TSC-related epilepsy, with plans to submit a response as soon as possible [4][7]. Market Context - Tuberous Sclerosis Complex (TSC) is a rare genetic disorder affecting the mTOR pathway, leading to tumor growth in multiple organs, with epilepsy being the most common health issue, affecting 80% to 90% of TSC patients [9]. - Approximately 45,000 people in the U.S. are affected by TSC-related epilepsy, with over 60% of patients remaining refractory to existing antiepileptic therapies despite multiple approved treatments [9].